Payment overview · 2025
General Payments
$492.07
19 reported records · 11 companies
Healthcare provider profile · identity verified
Woojin Joo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1780110338
Verified facts
What the public records show
CMS Open Payments records show Woojin Joo, MD received $492.07 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.38 | 24.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.57 | 17.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.48 | 11.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.64 | 11.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.71 | 6.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $30.02 | 6.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.21 | 5.7% | 1 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $24.92 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.61 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.45 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.08 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.07 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.02 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $85.57 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.57 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.48 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.71 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $30.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 187 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 43 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 217 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
187 | 64 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 148 |
| Vascepa | Icosapent Ethyl | 317 | 69 |
| Losartan Potassium | Losartan Potassium | 304 | 112 |
| Metformin Hcl | Metformin Hcl | 245 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 64 |
| Jardiance | Empagliflozin | 217 | 56 |
| Lidocaine | Lidocaine | 204 | 67 |
| Omeprazole | Omeprazole | 192 | 73 |
| Creon | Lipase/Protease/Amylase | 187 | 64 |
| Donepezil Hcl | Donepezil Hcl | 165 | 43 |
| Azithromycin | Azithromycin | 157 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 36 |
| Simvastatin | Simvastatin | 102 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 30 |
| Rybelsus | Semaglutide | 77 | 11 |
| Memantine Hcl Er | Memantine Hcl | 76 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 71 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 27 |
| Myrbetriq | Mirabegron | 65 | 13 |
| Januvia | Sitagliptin Phosphate | 64 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 61 | 30 |
| Naproxen | Naproxen | 55 | 50 |
| Trazodone Hcl | Trazodone Hcl | 55 | 24 |
| Alendronate Sodium | Alendronate Sodium | 49 | 19 |
| Ozempic | Semaglutide | 48 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 16 |
| Eliquis | Apixaban | 43 | 13 |
| Amoxicillin | Amoxicillin | 42 | 30 |
| Famotidine | Famotidine | 42 | 27 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Atenolol | Atenolol | 40 | 14 |
| Gabapentin | Gabapentin | 39 | 19 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | 14 |
| Ketoconazole | Ketoconazole | 38 | 17 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Furosemide | Furosemide | 34 | 17 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 21 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Lisinopril | Lisinopril | 31 | 12 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Restasis | Cyclosporine | 27 | 13 |
| Meloxicam | Meloxicam | 26 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | 11 |
| Temazepam | Temazepam | 25 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 11 |
| Cyclosporine | Cyclosporine | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 18 |
| Linzess | Linaclotide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | 12 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Baclofen | Baclofen | 21 | 15 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 18 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 14 |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 16 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.07 · 19 records | Lilly USA, LLC | AFREZZA, CREON, ELIQUIS, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, The Cologuard Plus Collection Kit, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error